Sign in

    Bradley Canino

    Managing Director and Biotechnology Equity Research Analyst at Stifel

    Bradley Canino is a Managing Director and Biotechnology Equity Research Analyst at Guggenheim Securities, with deep specialization in oncology and precision medicine. Previously Director at Stifel Financial, he has covered over 35 biopharma stocks, including Blueprint Medicines and several mid-to-small-cap biotechnology firms, with a recent TipRanks analyst success rate near 25% and an average return of approximately -11.5%. Canino began his equity research career at UBS, followed by roles at SVB Leerink and Credit Suisse, and joined Stifel in 2021 before moving to Guggenheim in 2025. He holds an MBA and B.S. in Accounting from Le Moyne College, is a certified CPA, and maintains FINRA securities registrations.

    Bradley Canino's questions to Celcuity (CELC) leadership

    Bradley Canino's questions to Celcuity (CELC) leadership • Q4 2024

    Question

    Bradley Canino from Stifel asked about the extent of data Celcuity plans to share in its Q2 top-line release for VIKTORIA-1 and whether they have received investigator feedback regarding Roche's safety letters for inavolisib.

    Answer

    CEO Brian Sullivan confirmed they would present median PFS and hazard ratios for the wild-type cohort, with a fuller presentation at a future medical meeting. Regarding inavolisib, he noted the known challenges with PI3K alpha inhibitors and positioned gedatolisib's potential advantages in tolerability and broader patient applicability, independent of metabolic or PIK3CA status.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Celcuity (CELC) leadership • Q3 2024

    Question

    Bradley Canino of Stifel inquired about the focus of the updated analysis to be presented at the San Antonio Breast Cancer Symposium. He also asked if Celcuity views emerging data from oral SERD and CDK doublet combinations as a potential competitive threat and how the company plans to analyze that data.

    Answer

    Executive Brian Sullivan explained that at the symposium, Celcuity will present posters with extended follow-up data from its Phase Ib trial and further details on gedatolisib's mechanism of action. Regarding potential competitors, Sullivan acknowledged the relevance of the data but stressed the importance of analyzing subgroups, particularly patients with prior CDK4/6 inhibitor treatment, to make accurate, 'like-for-like' comparisons with the VIKTORIA-1 population.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Syndax Pharmaceuticals (SNDX) leadership

    Bradley Canino's questions to Syndax Pharmaceuticals (SNDX) leadership • Q4 2024

    Question

    Bradley Canino of Stifel asked about the expected cadence for activating the remaining high-priority accounts for Revuforj and how the launch is tracking compared to historical AML targeted therapy analogs.

    Answer

    CCO Steven Closter explained that while a specific cadence won't be provided, they expect to activate accounts "one by one" throughout the year, noting Tier 1 accounts are activating faster than Tier 2. He added that it's too early to compare to analogs but highlighted Revuforj's unique advantages, such as high diagnostic testing rates and a focus on securing paid claims from the start.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Syndax Pharmaceuticals (SNDX) leadership • Q3 2024

    Question

    Bradley Canino from Stifel Financial Corp. asked about the commercial expectations for Revumenib maintenance therapy post-transplant and what Syndax is looking for in the upcoming BEAT AML data to finalize its frontline pivotal trial.

    Answer

    CEO Michael Metzger stated that the 43% maintenance rate in the AUGMENT-101 trial is encouraging and expects the practice to continue post-launch. Dr. Neil Gallagher, President and Head of R&D, clarified that while the BEAT AML update will provide more patient data, it is not a rate-limiting factor for initiating the Phase III frontline study, which is proceeding in parallel.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to ARVINAS (ARVN) leadership

    Bradley Canino's questions to ARVINAS (ARVN) leadership • Q4 2024

    Question

    Bradley Canino asked how Arvinas will view the results from competing frontline Phase III oral SERD trials from Roche and AstraZeneca, which are expected to launch around the same time as Arvinas's vepdegestrant combination trial.

    Answer

    Chief Medical Officer Noah Berkowitz stated that these competing trials are not expected to impact the operational feasibility of Arvinas's study. He noted that positive results from competitors would generate excitement in the space but emphasized the fundamental difference between SERDs and PROTACs, expressing the expectation that a PROTAC could deliver stronger results.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to ARVINAS (ARVN) leadership • Q3 2024

    Question

    Bradley Canino of Stifel asked for expectations on the upcoming abemaciclib combination data relative to the strong palbociclib combo data presented last year, questioning if that sets the bar for future CDK combinations.

    Answer

    CEO John Houston clarified that the patient populations differ, as the abemaciclib trial is 100% post-CDK4/6 experienced versus 86% for the palbociclib study. CMO Noah Berkowitz added that the abemaciclib data will have shorter follow-up, so investors should focus on response rates and safety rather than a mature PFS comparison.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Kymera Therapeutics (KYMR) leadership

    Bradley Canino's questions to Kymera Therapeutics (KYMR) leadership • Q4 2024

    Question

    Bradley Canino of Stifel Financial Corp. asked how the small, 20-patient, 4-week Phase Ib study for KT-621 will serve as a useful tool to build conviction in the drug's profile, given it is not a definitive patient assessment.

    Answer

    CEO Nello Mainolfi explained that the Phase Ib's primary goal is to generate robust biomarker data in patients to confirm that a STAT6 degrader acts like dupilumab. He believes this data will be a powerful tool to demonstrate the 'dupi in a pill' concept and help accelerate recruitment for the larger Phase IIb studies.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Kymera Therapeutics (KYMR) leadership • Q3 2024

    Question

    Bradley Canino of Stifel inquired about the clinical development plan for the STAT6 program following the healthy volunteer study, asking about the optimal Th2 disease for initial patient testing and whether biomarker data could accelerate development.

    Answer

    CEO Nello Mainolfi suggested that a short biomarker study in atopic dermatitis (AD) patients could be highly informative, leveraging the well-established dupilumab biomarker signature in skin to demonstrate pathway blockade. He indicated this approach could enable a rapid move into larger studies across multiple relevant Th2 diseases.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Summit Therapeutics (SMMT) leadership

    Bradley Canino's questions to Summit Therapeutics (SMMT) leadership • Q4 2024

    Question

    Bradley Canino of Stifel asked about the primary strategic goal of the Pfizer ADC collaboration, whether it's to enhance therapy beyond existing benchmarks or to expand ivonescimab's use outside of lung cancer. He also questioned how Summit will demonstrate comparable efficacy between Western and Chinese patients in the HARMONi data.

    Answer

    An executive responded that the Pfizer collaboration serves both purposes but is more heavily focused on expanding ivonescimab into solid tumors beyond lung cancer, where ADC data has shown significant promise. Regarding data comparability, an executive confirmed that Summit will provide granular data in presentations at major medical conferences to clearly demonstrate the efficacy and safety profiles across both Eastern and Western patient populations.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Summit Therapeutics (SMMT) leadership • Q3 2024

    Question

    Bradley Canino from Stifel asked about the rationale for adding PFS as a primary endpoint to the HARMONi-3 trial, management's confidence in achieving an Overall Survival (OS) benefit, the data reporting plan for the expanded trial, and the company's view on the competitive landscape for PD-1/VEGF bispecifics.

    Answer

    CMO Dr. Allen Yang stated the decision was driven by the striking PFS benefit seen in HARMONi-2 and that confidence in OS remains unchanged. Executive Dave Gancarz confirmed communications with the FDA occurred prior to the change and that data for the single HARMONi-3 trial would be analyzed together. Gancarz also expressed high confidence in ivonescimab's unique engineering compared to emerging competitors.

    Ask Fintool Equity Research AI

    Bradley Canino's questions to Kura Oncology (KURA) leadership

    Bradley Canino's questions to Kura Oncology (KURA) leadership • Q3 2024

    Question

    Bradley Canino of Stifel asked for Kura's perspective on collaborating with European cooperative groups for frontline trials versus pursuing a fully company-sponsored approach.

    Answer

    CEO Dr. Troy Wilson acknowledged the value of cooperative groups for specific populations, like their LLS collaboration for pediatrics. However, for the core, high-value pivotal trials in 7+3 and ven/aza, he confirmed Kura will run its own sponsored studies to maintain full control over design, timelines, and data, as these are commercially critical programs.

    Ask Fintool Equity Research AI